The current research examines a novel method for the design of antibody-based drugs against G protein–coupled receptors (GPCRs), proteins involved in numerous physiological processes and often the targets of pharmacological intervention. GPCRs have traditionally been treated with small-molecule drugs; these, however, have the potential to produce unwanted side effects as a result of their lack of specificity. Although antibody-based drugs can potentially be a better option, their design for GPCR targeting is especially challenging as a result of the nature of these proteins.